From Oregon Health & Science University, Portland, Oregon; University of Washington, Seattle, and Spectrum Research, Tacoma, Washington.
Ann Intern Med. 2017 Apr 4;166(7):480-492. doi: 10.7326/M16-2458. Epub 2017 Feb 14.
A 2007 American College of Physicians guideline addressed pharmacologic options for low back pain. New evidence and medications have now become available.
To review the current evidence on systemic pharmacologic therapies for acute or chronic nonradicular or radicular low back pain.
Ovid MEDLINE (January 2008 through November 2016), Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and reference lists.
Randomized trials that reported pain, function, or harms of systemic medications versus placebo or another intervention.
One investigator abstracted data, and a second verified accuracy; 2 investigators independently assessed study quality.
The number of trials ranged from 9 (benzodiazepines) to 70 (nonsteroidal anti-inflammatory drugs). New evidence found that acetaminophen was ineffective for acute low back pain, nonsteroidal anti-inflammatory drugs had smaller benefits for chronic low back pain than previously observed, duloxetine was effective for chronic low back pain, and benzodiazepines were ineffective for radiculopathy. For opioids, evidence remains limited to short-term trials showing modest effects for chronic low back pain; trials were not designed to assess serious harms. Skeletal muscle relaxants are effective for short-term pain relief in acute low back pain but caused sedation. Systemic corticosteroids do not seem to be effective. For effective interventions, pain relief was small to moderate and generally short-term; improvements in function were generally smaller. Evidence is insufficient to determine the effects of antiseizure medications.
Qualitatively synthesized new trials with prior meta-analyses. Only English-language studies were included, many of which had methodological shortcomings. Medications injected for local effects were not addressed.
Several systemic medications for low back pain are associated with small to moderate, primarily short-term effects on pain. New evidence suggests that acetaminophen is ineffective for acute low back pain, and duloxetine is associated with modest effects for chronic low back pain.
Agency for Healthcare Research and Quality. (PROSPERO: CRD42014014735).
2007 年美国医师学院的指南针对腰痛的药物治疗选择进行了探讨。新的证据和药物现已面世。
回顾关于急性或慢性非神经根性或神经根性腰痛的全身性药物治疗的现有证据。
Ovid MEDLINE(2008 年 1 月至 2016 年 11 月)、Cochrane 对照试验中心注册库、Cochrane 系统评价数据库和参考文献列表。
报告疼痛、功能或全身性药物与安慰剂或其他干预措施比较的安全性的随机试验。
一名调查员提取数据,第二名调查员验证准确性;两名调查员独立评估研究质量。
试验数量从 9 项(苯二氮䓬类)到 70 项(非甾体抗炎药)不等。新证据表明,对乙酰氨基酚对急性腰痛无效,非甾体抗炎药对慢性腰痛的益处小于之前观察到的,度洛西汀对慢性腰痛有效,而苯二氮䓬类药物对神经根病变无效。对于阿片类药物,证据仍然仅限于短期试验,表明对慢性腰痛有适度的效果;试验的设计目的不是评估严重的危害。骨骼肌松弛剂在急性腰痛的短期疼痛缓解方面有效,但会引起镇静。全身皮质类固醇似乎没有效果。对于有效的干预措施,疼痛缓解为小至中度,通常为短期;功能的改善通常较小。证据不足以确定抗惊厥药物的效果。
对先前的荟萃分析进行了新试验的定性综合。仅纳入了英语研究,其中许多研究存在方法学上的缺陷。没有涉及用于局部效果的注射药物。
几种治疗腰痛的全身性药物对疼痛具有小至中度、主要为短期的影响。新证据表明,对乙酰氨基酚对急性腰痛无效,度洛西汀与慢性腰痛的适度效果相关。
美国医疗保健研究与质量局。(PROSPERO:CRD42014014735)